group-women-sports-teams

Newsroom

Take a look inside our world

Press Releases

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
View all press releases

Our Stories

Teva scientist interacting with a large green abstract network graphic illustrating biological pathways and potential pathways for business growth. Leadership Global Operations Global Growth Biosimilars

Sustaining Teva’s Generics Powerhouse in the Acceleration Phase

 Teva scientist using microscope working on research for innovative medicines Leadership Research & Development Growth

Step Up Innovation

 Teva scientist looking at stylized DNA strand representing acceleration phase of pivot to growth strategy Leadership Research & Development Growth Innovation

Pivot to Growth: The Acceleration Phase

 Leadership Innovation Neuroscience Growth

Delivering on Growth Engines

 Innovation Growth

Teva in 2025: Innovation drives third consecutive year of growth

 Access to Medicine Sustainability Social Impact

Supporting Healthier Communities

 Evan Lippman, Teva’s Executive Vice President of Business Development Global Innovation Research & Development

“I Think People are Starting to Get That There’s a Lot of Upside at Teva”

 Global Innovation Research & Development Patient Focus

Teva Rise: Accelerating Pharma Innovation Globally

 Sustainability Impact

Using Antibiotics Wisely. Making Them Responsibly.

 Global Innovation Global Operations

Building the Factory of the Future with Augmented Reality

 View all stories

Contacts for Media Inquiries

Grace Ann Arnold

  United States  

+1-973-2653670
GraceAnn.Arnold@tevapharm.com

Eden Klein

Israel & Corporate

+972-3-9062645
Eden.Klein@teva.co.il

Fiona Cohen

Europe

fiona.cohen@tevaeu.com

Teva Media Assets

These proprietary media assets are available for download and are intended for non-commercial media use and research only.

Download Logo Download Teva B-Roll

Connect with us on social media

Follow us on Facebook

Go to facebook.com

Follow us on Linkedin

Go to linkedin.com

Follow us on Twitter

Go to twitter.com